Last reviewed · How we verify
CBP501 and Cisplatin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CBP501 and Cisplatin (CBP501 and Cisplatin) — CanBas Co. Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CBP501 and Cisplatin TARGET | CBP501 and Cisplatin | CanBas Co. Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CBP501 and Cisplatin CI watch — RSS
- CBP501 and Cisplatin CI watch — Atom
- CBP501 and Cisplatin CI watch — JSON
- CBP501 and Cisplatin alone — RSS
Cite this brief
Drug Landscape (2026). CBP501 and Cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/cbp501-and-cisplatin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab